Scarica l'app Stockscreener
15.80
5.45%
-0.91
Dopo l'orario di chiusura:
15.78
-0.02
-0.13%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$16.71
Aprire:
$16.71
Volume 24 ore:
314.15K
Relative Volume:
0.75
Capitalizzazione di mercato:
$292.50M
Reddito:
$1.93M
Utile/perdita netta:
$-7.96M
Rapporto P/E:
-0.00447
EPS:
-3530.8178
Flusso di cassa netto:
$-36.78M
1 W Prestazione:
-8.72%
1M Prestazione:
+10.80%
6M Prestazione:
+48.29%
1 anno Prestazione:
+112.94%
Intervallo 1D:
$15.45
$17.14
Intervallo di 1 settimana:
$15.45
$18.02
Portata 52W:
$3.39
$20.72
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Nome
Avalo Therapeutics Inc
Settore
Industria
Telefono
410-522-8707
Indirizzo
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
15.80 | 292.50M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Iniziato | Guggenheim | Buy |
| 2025-12-18 | Iniziato | Mizuho | Outperform |
| 2025-09-17 | Reiterato | H.C. Wainwright | Buy |
| 2025-09-05 | Iniziato | TD Cowen | Buy |
| 2025-08-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-03-25 | Iniziato | Jefferies | Buy |
| 2025-03-25 | Iniziato | Stifel | Buy |
| 2025-02-28 | Iniziato | Piper Sandler | Overweight |
| 2025-02-21 | Iniziato | Wedbush | Outperform |
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-10-24 | Iniziato | H.C. Wainwright | Neutral |
| 2024-04-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-09-24 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Avalo Therapeutics Inc Borsa (AVTX) Ultime notizie
Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference - Yahoo Finance
Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Can Avalo Therapeutics Inc. stock hit analyst price targets2025 Earnings Surprises & Safe Swing Trade Setups - Naître et grandir
Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference - Defense World
FMR LLC holds 2.13M shares of Avalo Therapeutics (NASDAQ: AVTX) — 11.5% - Stock Titan
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Ascendis Pharma (ASND) and Avalo Therapeutics (AVTX) - The Globe and Mail
Avalo Therapeutics (AVTX) awards 80,000 stock options to Chief Legal Officer - Stock Titan
Avalo Therapeutics (AVTX) CSO awarded 95,000 stock options - Stock Titan
[Form 4] Avalo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) CBO awarded 95,000 stock options - Stock Titan
Avalo Therapeutics (AVTX) CFO awarded 105,000 stock options as equity compensation - Stock Titan
Avalo Therapeutics (AVTX) CEO awarded 286,000-share stock option grant - Stock Titan
Millennium Management LLC Acquires Additional Shares in Avalo Th - GuruFocus
RWA Wealth Partners LLC Cuts Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
AVTX Should I Buy - Intellectia AI
Avalo Therapeutics Highlights AVTX-009 HS Phase II Catalyst, Cash Runway at Oppenheimer Conference - Yahoo Finance
AVTX: AVTX-009 targets central HS inflammation, with pivotal phase II data expected next quarter - TradingView
TD Cowen reiterates Avalo Therapeutics stock rating citing phase II opportunity - Investing.com South Africa
Piper Sandler Initiates Coverage of Avalo Therapeutics (AVTX) with Overweight Recommendation - MSN
TD Cowen reiterates Avalo Therapeutics stock rating citing phase II opportunity By Investing.com - Investing.com South Africa
Avalo Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Patient Square Capital LP Makes New Investment in Avalo Therapeutics, Inc. $AVTX - MarketBeat
AVTXAvalo Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Aberdeen Group plc Makes New $925,000 Investment in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Reviewing Avalo Therapeutics (NASDAQ:AVTX) and VYNE Therapeutics (NASDAQ:VYNE) - Defense World
Balyasny Asset Management L.P. Reduces Stake in Avalo Therapeuti - GuruFocus
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Millennium discloses 4.8% Avalo Therapeutics (AVTX) ownership position - Stock Titan
Can Avalo Therapeutics Inc. outperform under higher oil pricesJuly 2025 PreEarnings & Low Risk High Win Rate Picks - mfd.ru
Is Avalo Therapeutics Inc. stock overvalued by current metricsJuly 2025 Final Week & Consistent Profit Trade Alerts - mfd.ru
How Avalo Therapeutics Inc. stock reacts to global recession fearsWeekly Stock Recap & Community Shared Stock Ideas - mfd.ru
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa - MarketBeat
AVTX: Phase 2b LOTUS trial for AVTX-009 in HS nears Q2 data, targeting rapid phase 3 and new indications - TradingView
What analysts say about Avalo Therapeutics Inc. stockJuly 2025 Breakouts & AI Driven Price Forecasts - mfd.ru
SilverArc Capital and Devesh Gandhi report 2.83% Avalo Therapeutics (AVTX) holding - Stock Titan
Dow Update: Will Avalo Therapeutics Inc outperform the market in YEARRate Hike & Long-Term Capital Growth Ideas - baoquankhu1.vn
Piper Sandler Keeps Their Buy Rating on Avalo Therapeutics (AVTX) - The Globe and Mail
Avalo Therapeutics shares jump as Guggenheim starts coverage with buy - MSN
Biotech firm Avalo will stream two investor talks in February - Stock Titan
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case - Benzinga
Guggenheim Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - Nasdaq
Guggenheim Initiates Coverage on Avalo Therapeutics (AVTX) with - GuruFocus
Avalo Therapeutics stock rises after Guggenheim initiates with Buy rating By Investing.com - Investing.com Australia
Avalo Therapeutics stock rises after Guggenheim initiates with Buy rating - Investing.com
Guggenheim Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX) - MarketBeat
Guggenheim initiates Avalo Therapeutics stock with Buy rating on IL-1β therapy - Investing.com UK
Guggenheim initiates Avalo Therapeutics stock with Buy rating on IL-1β therapy By Investing.com - Investing.com India
Avalo Therapeutics Inc Azioni (AVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):